If you have a myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), or another bone marrow failure disorder, Rush can help. We welcome patients seeking treatment or a second opinion after any of the following diagnoses:
-- Myelodysplastic syndromes (MDS)
-- MDS/MPN overlap syndromes, including chronic myelomonocytic leukemia
-- Polycythemia vera
-- Essential thrombocythemia
-- Aplastic anemia
-- Paroxysmal nocturnal hemoglobinuria (PNH)
These disorders are closely related and uncommon. They also cause different symptoms in different people, so it takes an experienced specialist to properly diagnose and treat them.
At Rush, Jamile Shammo, MD, focuses exclusively on rare blood and bone marrow disorders. She leads a team of experts who meet every two weeks to discuss new patients' diagnoses and treatment plans.
MEET OUR TEAM
Wei-Tong Hsu, MD, received her medical degree from the Beijing Medical College and had completed her Clinical Cytogenetics Fellowship at Cedars-Sinai Medical Center, University of California at Los Angeles (UCLA) Intercampus Medical Genetics Training Program. She joined Department of Pathology at Rush University Medical Center after completing her fellowship in Clinical Cytogenetics. Dr. Hsu is a board certified clinical cytogeneticist by the American Board of Medical Genetics.
Dr. Hsu is currently the director for the Clinical Cytogenetics Laboratory at Department of Pathology in Rush University Medical Center. She reviews a wide spectrum of cytogenetic tests including chromosome, FISH, and genomic microarray analyses, on constitutional and oncological samples.
Dr. Hsu’s interests focus on understanding the cytogenetic basis of genetic disorders, cytogenetic and molecular genetic changes in neoplasm, and molecular karyotyping and microarray studies in constitutional disorders and neoplasm.
|Medical or Graduate Education:
||Albert Einstein College of Medicine |
||McGaw Medical Center of Northwestern University - Anatomic
||Rush University Medical Center - Anatomic Pathology |
||Stanford Hospital and Clinics - Membrane Pathobiology |
- Bone cancer
- Leukemias, acute and chronic
- Myelodysplastic syndrome
- Myeloproliferative disorders
- Soft tissue tumors
Jamile M. Shammo, MD, is an associate
professor of medicine and pathology, Section of Hematology and Stem Cell
Transplantation, Division of Hematology/Oncology, at Rush University Medical
Center in Chicago, Illinois, where she spearheads the MDS/MPN/Bone Marrow
Failure Program. She is involved in research activities and administration, as
a principal investigator of clinical trials in her area of expertise, and as a
co-chair for the protocol review and monitoring committee at Rush Cancer
Institute. She is recognized nationally for her expertise in bone marrow failure
syndromes, and was chosen to serve as a national coordinator for the PNH
registry. Dr. Shammo earned her medical degree with honors from Aleppo Medical School
in Syria, after which she pursued further education in the US and completed
residencies in Pathology and Internal Medicine at McGaw Medical Center of
Northwestern University in Evanston, Illinois, as well as a 3-year fellowship
in the Division of Hematology/Oncology at University of Chicago.
Dr Shammo is board certified in anatomic and clinical pathology,
internal medicine, and hematology, and board eligible in oncology. Dr Shammo is
a fellow of the American Society of Clinical Pathologists and American College
of Physicians. She received the Department of Medicine Service and Teaching
Award from Rush University Medical Center in 2003. Dr. Shammo speaks fluent
Dr Shammo has authored or coauthored over 100 publications, including
abstracts, posters, book chapters and online CME activities, as well as
articles published in Blood, American Journal of Hematology, Journal of
Clinical Oncology, Clinical Lymphoma, Journal of Heart and Lung
Transplantation, Cytotherapy, and American Journal of Clinical
Pathology, among others. Additionally, she served as a reviewer for several
medical journals and as an editor for the Journal of Clinical Oncology. She
has designed and is currently involved as principal investigator for many
clinical trials related to chronic myelogenous leukemia, myeloproliferative
neoplasms, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes.
As an invited speaker, Dr Shammo has presented her research at national and
international meetings and conferences.
What Your Diagnosis Means
These disorders have more in common than complicated names. In each case,
bone marrow does not make enough healthy blood cells. (Bone marrow, a spongy
substance inside your bones, normally works as a cell “factory.”)
But each diagnosis means something different:
- MDS means you don't have enough of at least one type of
blood cell. It also means that some of your blood cells are abnormally shaped.
- Aplastic anemia means you do not have enough bone marrow to
make the right amount of blood cells.
- PNH means that your red blood cells are missing a protein
they need to survive. As a result, your immune system breaks them apart.
- MDS/MPN overlap syndromes are like MDS in some ways and
neoplasms (MPN) in others.
All myeloproliferative neoplasms involve having too many blood cells. But
each diagnosis means something different:
- Polycythemia vera means you have too many red blood cells.
You might also have too many white blood cells or platelets (a kind of cell that
helps your blood to clot).
- Essential thrombocythemia means your blood has too many
- Myelofibrosis means you have abnormal blood cells that grow
too quickly and take over your bone marrow (a spongy material inside your bones
that produces cells). This causes scar tissue to grow in your bone marrow and
stops it from working normally.
Before your appointment, the team at Rush will meet to talk about your care.
They will look at any blood or bone marrow tests you have had and discuss the
treatments most likely to work for you.
Depending on your condition, you might need one or more of the following:
After you arrive, Jamile
Shammo, MD, will examine you, explain your options and work with you to
create a treatment plan that meets your needs. If you wish, the team at Rush
will be happy to work with your regular hematologist to carry out your
Rush welcomes patients seeking second
opinions. If you have been diagnosed with an MDS or another bone marrow
failure disorder, you may want to get a second opinion to make sure that the
diagnosis is accurate and that your treatment plan is the best one for you.
Doctors at Rush are conducting research on new treatments for bone marrow
failure disorders. Through clinical trials, they
can offer some patients medications that are not widely available otherwise.
In addition to clinical trials, doctors at Rush participate in registry
studies, which involve collecting information about many patients to help
improve understanding of a condition. Jamile
Shammo, MD, is one of four physicians nationwide in charge of the PNH
registry, an international research project whose goal is to help doctors and
researchers learn more about PNH.
Accreditation and Recognition
Rush Cancer Center MDS Clinic
1725 W. Harrison St.
Professional Building II
Chicago, IL 60612
Phone: (312) 942-5544